Shots:

• The companies collaborated to explore developing PDTs for the treatment of patients with selected indications within the gastrointestinal space
• The focus of the agreement is to merge Pear’s expertise in PDTs with Ironwood’s GI franchise and clinical expertise and to expand Pear’s portfolio outside the central nervous system
• The collaboration will provide an opportunity to develop first-in-class therapies- helping patients with GI disease to reach better outcomes

Click here to­ read full press release/ article | Ref: Pear Therapeutics  | Image: PMLive